Skip to main content
Afyren logo

Afyren — Investor Relations & Filings

Ticker · ALAFY ISIN · FR0014005AC9 LEI · 969500XKOIIX6JRUAY14 PA Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2024-04-08 Transaction in Own Shar…
Country FR France
Listing PA ALAFY

About Afyren

https://afyren.com/en/

Afyren is a greentech company that develops and produces biobased organic acids as sustainable alternatives to petroleum-derived molecules. Utilizing a proprietary fermentation technology, the company transforms non-food biomass co-products from agriculture into a range of seven distinct carboxylic acids. This process operates on a circular, zero-waste model, significantly reducing the carbon footprint compared to conventional petrochemical production. The resulting biomolecules serve as key ingredients for manufacturers in diverse sectors, including human and animal nutrition, cosmetics, and fine chemicals, enabling the creation of low-carbon, biobased consumer products.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of own share transactions). The content explicitly details transactions on own shares ('transactions sur actions propres') executed by AFYREN between March 25 and March 28, 2024, including volume and weighted average price. This directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance), which is classified as code POS.
2024-04-08 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release dated April 2, 2024, announcing the audited annual financial results for the year ended December 31, 2023. It contains key financial highlights (simplified income statement and balance sheet), management commentary, operational updates (AFYREN NEOXY), ESG performance, and future outlook. This structure strongly indicates a release of annual financial performance data. However, the final section explicitly states: "La Société mettra à la disposition du public et déposera auprès de l'Autorité des marchés financiers son Rapport Financier Annuel 2023 au plus tard le 12 avril 2024." This means the document itself is not the full Annual Report (10-K) but rather the initial announcement of the results, which aligns best with the Earnings Release (ER) category, as it provides the key figures and context before the formal filing. Since it covers the full fiscal year, it is more comprehensive than a typical quarterly earnings release, but in the context of the provided definitions, 'ER' is the closest fit for an initial results announcement, distinct from the comprehensive '10-K' which is the official filing itself, or 'IR' which is typically for interim reports. Given the comprehensive nature of the financial tables, it borders on being a Management Discussion & Analysis (MDA) or a very detailed ER. However, the primary function here is the announcement of the annual results, making ER the most appropriate classification among the choices for a press release summarizing annual performance. FY 2023
2024-04-02 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is an 'Earnings Release' (ER). It provides a summary of audited annual financial results for the year ended December 31, 2023, including key highlights, management commentary, simplified P&L and balance sheet tables, and future outlook. While it mentions that the full annual financial report will be filed later, the document itself contains the substantive financial data and analysis typical of an earnings release announcement. It is not a full 10-K/Annual Report, nor is it a mere announcement of a report (RPA), as it provides detailed financial tables and performance metrics. FY 2023
2024-04-02 English
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares). The content explicitly details the volume and weighted average price of shares repurchased by AFYREN between March 18 and March 22, 2024. This directly corresponds to the definition of a company buying back or selling its own shares, which maps precisely to the 'Transaction in Own Shares' category.
2024-03-25 French
Inside Information / Other news releases
Environmental & Social Information Classification · 1% confidence The document is a press release announcing that AFYREN NEOXY received a €3.4 million milestone payment related to the AFTER-BIOCHEM project, which is funded by the Circular Bio-based Europe Joint Undertaking (CBE JU). This announcement details a specific financial event (receipt of grant funding/milestone payment) and provides updates on project progress and future outlook. It is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER) focusing on P&L/Balance Sheet highlights, or a transcript (CT). Since it is an announcement detailing a specific financial/operational update that is not a standard regulatory filing like 10-K or a formal earnings release, it best fits the category for Capital/Financing Update (CAP) as it relates directly to receiving grant funding which impacts capital structure/financing, or potentially Regulatory Filings (RNS) as a general corporate announcement. Given the focus on receiving a significant grant payment and project funding milestones, 'CAP' is a strong fit, but 'RNS' is often used for press releases announcing specific, non-standard financial achievements or project updates that don't fit the core financial reports. However, since it is a direct announcement of receiving funds related to a project, it is fundamentally a financing/capital event. I will classify it as a Capital/Financing Update (CAP) as the core subject is the receipt of grant money impacting the company's financial standing, though RNS is a close secondary option if CAP were too narrow. Given the definitions, CAP covers 'Updates on company fundraising, financing activities, or capital structure changes,' and receiving grant tranches falls under financing activities.
2024-03-21 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated March 21st announcing that AFYREN NEOXY received a new payment installment (€3.4 million) related to the European project AFTER-BIOCHEM, funded by the Circular Bio-based Europe Joint Undertaking (CBE JU). This announcement details the receipt of funds, project milestones, consortium partners, and future production targets (2024/2025). This type of announcement, focusing on specific financial milestones, grants, or project updates outside of standard periodic financial reports (like 10-K or IR), best fits the 'Capital/Financing Update' category, as it concerns the inflow of significant grant funding which impacts capital structure and operations. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), but rather a specific update on financing/funding received.
2024-03-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.